IVP concentrates AI capital on application layer with strong results
Liaw states most IVP AI investments are application-layer and expresses satisfaction; he sees Europe producing a scaling cohort of applied AI companies (e.g., Cradle in drug discovery) that…
European founders must target US expansion at $10-15M ARR, not $50M
Liaw observes the US-expansion threshold has dropped from ~$50M ARR to $10-15M; he advises sending a founding-team member to New York early to establish culture and hire US sales leadership…
Europe's pharma density fuels AI drug-discovery startups like Cradle
Proximity to global pharma giants (Novo Nordisk, Roche) in Europe gives AI application-layer companies immediate access to anchor customers, creating a defensible wedge for startups like Cr…
Liaw notes at least three to four European neobanks are larger than the single US equivalent, driven by inherent cross-border payment pain points that US founders don't face, giving Europe…